TG Therapeutics Inc. (NASDAQ:TGTX) Relative Strength Index (RSI) is 77.75, with weekly volatility at 12.49% and ATR at 2.75. The TGTX stock’s 52-week price range has touched low of $6.34 and a $31.97 high. Intraday shares traded counted 18.03 million, which was -1019.79% lower than its 30-day average trading volume of 1.61M. Its shares traded higher over the last trading session, gaining 40.85% on 12/10/20. The shares fell to a low of $32.88 before closing at $41.72. TGTX’s previous close was $29.62 while the outstanding shares total 119.18M. The firm has a beta of 2.11.
Investors have identified the Biotechnology company TG Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $5.32 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
TG Therapeutics Inc. (TGTX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For TGTX, the company has in raw cash 254.15 million on their books with 14.59 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 260.33 million total, with 77.67 million as their total liabilities.
TGTX were able to record -162.68 million as free cash flow during the Q3 2020 quarter of the year, this saw their quarterly net cash flow reduce by 141.52 million. In cash movements, the company had a total of -162.48 million as operating cash flow.
Potential earnings growth for TG Therapeutics Inc. (TGTX)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the Q3 2020 quarter of the year, TG Therapeutics Inc. recorded a total of 38000.0 in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.0% coming in sequential stages and their sales for the Q3 2020 quarter reducing by 0.0%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 38000.0 trying to sell their products during the last quarter, with the result yielding a gross income of 85.76 million. This allows shareholders to hold on to 119.18M with the recently reported earning now reading -0.73 cents per share. This is a figure that compared to analyst’s prediction for their Q3 2020 (-0.73 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.78 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TGTX sounds very interesting.
Is the stock of TGTX attractive?
In related news, 10% Owner, RA CAPITAL MANAGEMENT, L.P. sold 158,589 shares of the company’s stock in a transaction that recorded on Sep 09. The sale was performed at an average price of 25.81, for a total value of 4,092,738. As the sale deal closes, the Director, KENNEDY WILLIAM JAMES now sold 7,745 shares of the company’s stock, valued at 141,501. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.10%.
7 out of 7 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on TG Therapeutics Inc.. 0 analysts has assigned a Sell rating on the TGTX stock. The 12-month mean consensus price target for the company’s shares has been set at $47.43.